Metastatic Breast Cancer is incurable. There is therefore an urgent need to develop therapies to prevent metastatic breast cancer. Our previous work has demonstrated that the Runx2 transcriptional co-activator, CBFβ, is required for the expression of metastatic genes in breast cancer cells. The aim of this project is to determine the role of CBFβ, in the formation of metastases and identify new therapeutic targets to prevent metastasis. The project uses ChIP-seq, RNA-seq and microarray technologies combined with novel 3-D cell co-culture systems to identify genes that promote metastasis in breast cancer. More information can be found at: http://paulshorelab.org/
To apply for this PhD project please see: www.ls.manchester.ac.uk/phdprogrammes/howtoapply Also see our International Brochure www.ls.manchester.ac.uk/phdprogrammes/internationalbiosciences
Mendoza-Villanueva, D., Zeef, L. & Shore, P (2011). Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFbeta-dependent expression of the Wnt antagonist, Sclerostin. Breast Cancer Res, 13(5), R106.
Deng W, Lopez-Camacho C Tang J-Y, Mendoza-Villanueva D, Maya-Mendoza, Jackson D.A, and Shore P. (2012). Cytoskeletal protein filamin A is a nucleolar protein that suppresses ribosomal RNA gene transcription. PNAS 109 (5), 1524.
Owens TW, Rogers RL, Best S, Ledger A, Mooney AM, Ferguson A, Shore P, Swarbrick A, Ormandy CJ, Simpson PT, Carroll JS, Visvader JE, Naylor MJ. (2014) Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer. Cancer Res. Sep 15;74(18):5277-86.
Mendoza-Villanueva D, Deng W, Lopez-Camacho C, Shore P. (2010). The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells. Molecular Cancer, 9(171),
Shore P. (2005). A role for Runx2 in normal mammary gland and breast cancer bone metastasis. Journal of cellular biochemistry, 96(3), 484-9.